Open AccessFrataxin levels in peripheral tissue in Friedreich ataxia
Author(s) -
Lazaropoulos Michael,
Dong Yina,
Clark Elisia,
Greeley Nathaniel R.,
Seyer Lauren A.,
Brigatti Karlla W.,
Christie Carlton,
Perlman Susan L.,
Wilmot George R.,
Gomez Christoper M.,
Mathews Katherine D.,
Yoon Grace,
Zesiewicz Theresa,
Hoyle Chad,
Subramony Sub H.,
Brocht Alicia F.,
Farmer Jennifer M.,
Wilson Robert B.,
Deutsch Eric C.,
Lynch David R.
Publication year - 2015
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.225
Subject(s) - frataxin , ataxia , point mutation , buccal swab , trinucleotide repeat expansion , biology , genetics , mutation , microbiology and biotechnology , medicine , gene , iron binding proteins , allele , neuroscience
Objective Friedreich ataxia ( FRDA ) is an autosomal recessive ataxia resulting from mutations in the frataxin gene ( FXN ). Such mutations, usually expanded guanine–adenine–adenine ( GAA ) repeats, give rise to decreased levels of frataxin protein in both affected and unaffected tissues. The goal was to understand the relationship of frataxin levels in peripheral tissues to disease status. Methods Frataxin levels were measured in buccal cells and blood, and analyzed in relation to disease features. Site‐directed mutant frataxin was also transfected into human embryonic kidney cells to model results from specific point mutations. Results There was no evidence for change in frataxin levels over time with repeated measures analysis, although linear regression analysis of cross‐sectional data predicted a small increase over decades. GAA repeat length predicted frataxin levels in both tissues, and frataxin levels themselves predicted neurological ratings (accounting for age). Compound heterozygous patients for a GAA expansion and a point mutation in FXN generally had lower levels of frataxin than those homozygous for the presence of two GAA repeat expansions, though levels varied dramatically between tissues in some compound heterozygotes for point mutations. The G130V mutation led to decreased levels of frataxin in vitro as well as in vivo, while the R165C mutation produced normal immunoreactive levels of frataxin both in vitro and in vivo. Start codon mutations led to low levels of frataxin in buccal cells but preserved immunoreactive frataxin levels in blood. Interpretation The present data show that peripheral frataxin levels reflect disease features in FRDA , but emphasize the need for interpretation of such levels in the context of specific mutations.